sirtratumab vedotin

N/A

Report date: 2024/07/08 20:00:53

Base Information

Drug Namesirtratumab vedotin
Drug Alias NameASG-15MEAGS15C–SGD-1006AGS-15EHa15-10ac.1vcMMAEHa15-10ac12vcMMAE
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-SLITRK6
TargetsSLIT and NTRK-like protein 6Tubulin
Therapy Area/IndicationsCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAgensys IncSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen IncAgensys IncAstellas Pharma Global Development Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Transitional Cell

Other Information

ATC CodeN/A
Related LinksN/A